echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Scientists have found that acyclic vitamin A can selectively prevent cancer stem cells from producing new tumors

    Scientists have found that acyclic vitamin A can selectively prevent cancer stem cells from producing new tumors

    • Last Update: 2018-04-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, in a study published in the proceedings of the National Academy of Sciences, scientists found that acyclic vitamin A can target a class of cancer stem cells and prevent them from producing new tumors The team studied the transcriptome of cells exposed to acyclic vitamin A and found that they had low expression of MYCN compared with untreated cells, which is usually expressed in tumors and associated with poor prognosis Further experiments involving the intentional suppression of gene expression in cancer cells have shown that the decrease in MYCN expression results in slower cell cycle progression, proliferation and colony formation, and greater cell death, which means that acyclic retinoids on MYCN slow down the development of cancer The team then focused on the role of "cancer stem cells" - special cells that survive the impact of chemotherapy or other treatments, and then differentiate into new cancer cells, leading to recurrence The researchers found that the high expression of MYCN was related to the expression of many markers related to cancer stem cells The researchers performed liver biopsies on patients who had received acyclic retinoids after surgery for liver cancer, and found that the expression level of MYCN decreased at a high dose of 600 mg / D but not 300 mg / D, suggesting that the expression of MYCN in the response of acyclic vitamin A drugs (http:// may be the test (http:// An important component of the recurrence difference observed in The researchers looked at the data in the cancer genome map and found that the increased expression of MYCN was significantly associated with poor prognosis At present, Korea, Taiwan and Singapore are carrying out three phase clinical trials of acyclic retinoids (also known as peretinoin) to test the ability of the drug to prevent the recurrence of HCC.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.